The natural history of multiple system atrophy: a prospective European cohort studyGregor K. Wenning, Werner Poewe, Håkan Widner et al.|The Lancet Neurology|2013Cited by 533
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trialStéphane Palfi, Kyriacos Mitrophanous, Jean Marc Gurruchaga et al.|The Lancet|2014Cited by 436
Priorities in Parkinson's disease researchWassilios G. Meissner, Erwan Bézard, Mark Frasier et al.|Nature Reviews Drug Discovery|2011Cited by 430
Prevalence, Determinants, and Effect on Quality of Life of Freezing of Gait in Parkinson DiseaseSantiago Perez‐Lloret, Olivier Rascol, Laurence Nègre‐Pagès et al.|JAMA Neurology|2014Cited by 333
Trial of Lixisenatide in Early Parkinson’s DiseaseWassilios G. Meissner, Olivier Rascol, Philippe Rémy et al.|New England Journal of Medicine|2024Cited by 302